6965-69-1

Basic information

• Product Name: 2-FORMYL-4-NITROPHENOXYACETIC ACID
• Synonyms: 2-FORMYL-4-NITROPHENOXYACETIC ACID;2-(2-Formyl-4-nitrophenoxy)ethanoic acid, 2-(Carboxymethoxy)-5-nitrobenzaldehyde;2-(2-formyl-4-nitrophenoxy)acetic acid;Acetic acid, (2-formyl-4-nitrophenoxy)-
• CAS NO: 6965-69-1
• Molecular Formula: C₉H₇NO₆
• Molecular Weight: 225.15498
• Mol File: 6965-69-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 464.4°Cat760mmHg
• Flash Point: 234.7°C
• Appearance: /
• Density: 1.52g/cm³
• Vapor Pressure: 2E-09mmHg at 25°C
• Refractive Index: 1.626
• CAS DataBase Reference: 2-FORMYL-4-NITROPHENOXYACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-FORMYL-4-NITROPHENOXYACETIC ACID(6965-69-1)
• EPA Substance Registry System: 2-FORMYL-4-NITROPHENOXYACETIC ACID(6965-69-1)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 6965-69-1(Hazardous Substances Data)

Usage

General Description

2-FORMYL-4-NITROPHENOXYACETIC ACID is a chemical compound with the molecular formula C10H8N2O7. It is commonly used as a precursor in the synthesis of pharmaceuticals and agrochemicals. The compound contains a formyl group, a nitro group, and a phenoxyacetic acid group, making it a versatile building block for the development of various organic compounds. 2-FORMYL-4-NITROPHENOXYACETIC ACID has potential applications in the fields of medicine and agriculture due to its ability to be modified and transformed into different active ingredients. Overall, this compound plays a significant role in the production of various essential products for human health and agricultural productivity.

InChI:InChI=1/C9H7NO6/c11-4-6-3-7(10(14)15)1-2-8(6)16-5-9(12)13/h1-4H,5H2,(H,12,13)

Upstream product

• 90-02-8 salicylaldehyde 
• 97-51-8 5-Nitrosalicylaldehyde 
• 119197-73-8 2-Formyl-4-nitro-phenoxyessigsaeure-methylester-dimethylacetal 
• 79-11-8 chloroacetic acid 
• 24582-00-1 (2-formyl-4-nitrophenoxy)acetic acid methyl ester 
• 6280-80-4 2-Formylphenoxyacetic acid 

Downstream Products

• 24589-96-6 [(α-hydroxy-4-nitro-o-tolyl)oxy]-acetic acid 
• 24582-00-1 (2-formyl-4-nitrophenoxy)acetic acid methyl ester 
• 267644-49-5 5-nitro-1-benzofuran-2-carboxamide 
• 183288-46-2 5-(1-piperazinyl)benzofuran-2-carboxamide 
• 163521-12-8 vilazodone 
• 10242-12-3 5-nitrobenzofuran-2-carboxylic acid 
• 1354567-66-0 2-{2-[(allylmethylamino)methyl]-4-[4-(3-but-3-enyloxyphenyl)pyrimidin-2-ylamino]phenoxy}-1-pyrrolidin-1-ylethanone 
• 1354567-45-5 2-{2-[(allylmethylamino)methyl]-4-aminophenoxy}-1-pyrrolidin-1-ylethanone 
• 1354567-02-4 2-{2-[(allylmethylamino)methyl]-4-nitrophenoxy}-1-pyrrolidin-1-ylethanone 
• 1156670-01-7 5-nitro-2-(2-oxo-2-pyrrolidin-1-ylethoxy)benzaldehyde 
• 162509-46-8 (E)-2-methoxyiminomethyl-4-nitro-phenoxyacetic acid 
• 18761-31-4 5-nitrobenzofuran 
• 227286-81-9 (E)-(4-amino-2-hydroxyiminomethylhenoxy)acetic acid 
• 162509-45-7 (E)-(2-hydroxyiminomethyl-4-nitrophenoxy)acetic acid 

Relevant articles and documents

Design, synthesis, and biological evaluation of thiazolidine-2,4-dione conjugates as PPAR-γ agonists

A library of synthesized conjugates of phenoxy acetic acid and thiazolidinedione 5a-m showed potent peroxisome proliferator activated receptor-γ (PPAR-γ) transactivation as well as significant blood glucose lowering effect comparable to the standard drugs pioglitazone and rosiglitazone. Most of the compounds showed higher docking scores than the standard drug rosiglitazone in the molecular docking study. Compounds 5l and 5m exhibited PPAR-γ transactivation of 54.21 and 55.41%, respectively, in comparison to the standard drugs pioglitazone and rosiglitazone, which showed 65.94 and 82.21% activation, respectively. Compounds 5l and 5m significantly lowered the blood glucose level of STZ-induced diabetic rats. Compounds 5l and 5m lowered the AST, ALT, and ALP levels more than the standard drug pioglitazone. PPAR-γ gene expression was significantly increased by compound 5m (2.00-fold) in comparison to the standard drugs pioglitazone (1.5-fold) and rosiglitazone (1.0-fold). Compounds 5l and 5m did not cause any damage to the liver and could be considered as promising candidates for the development of new antidiabetic agents.

POLYMORPHIC FORM OF 5-(4-[4-(5-CYANO-1H-INDOL-3- YL)BUTYL]PIPERAZIN-1-YL) BENZOFURAN-2-CARBOXAMIDE

The present invention relates to a process for the preparation of 5-(4-[4-(5- cyano- 1 H-indol-3 -yl)butyl] piperazin- 1 -yl)benzofuran-2-carboxamide of Formula (1) or its pharmaceutically acceptable salt, solvates or hydrates thereof. In particular, the present invention provides a novel intermediate compound, 5-(4-substitutedpiperazin- 1-yl)benzofuran-2-carboxamide of Formula (X). The present invention further provides solid state form of 5-(4-[4-(5-cyano-1H-indol-3- yl) butyl]piperazin-1-yl)benzofuran-2-carboxamide of Formula (1) and process for its preparation.

SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS

The present invention relates to a class of substituted triazoles of formula (I) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction, particularly premature ejaculation (P.E.).